-
1 month ago | 
jdsupra.com | Michele Borens |Jeffrey Friedman |John Ormonde
In November 2024, voters approved Proposition M which provided for an overhaul of San Francisco’s gross receipts tax. (See our prior coverage here.) Proposition M changed the allocation and apportionment rules for most industries, generally requiring that three quarters of a taxpayer’s total receipts are allocated to the city on a market basis and one quarter are apportioned to the city using a payroll factor.
-
1 month ago | 00048-8?rss=yes&sz=64)
cell.com | Jeffrey Friedman
KeywordsobesityleptinmelanocortinsGLP1therapeuticsIntroductionFor any disease, an understanding of its causes and developing means for treating it represent critical milestones. Remarkably, 30 years after the discovery of leptin, we are now at this juncture for obesity—enormous progress has been made elucidating its causes, and there are now effective medicines for managing it.
-
2 months ago | 
openlegalblogarchive.org | Timothy A. Gustafson |Jeffrey Friedman
Midway through 2024, and without any notice, the California Franchise Tax Board (FTB) pulled all Technical Advice Memorandums from its website. Overnight, decades of responses by the FTB’s Legal Division to FTB staff requests regarding the interpretation of existing tax law or the application of existing tax law to a specific set of facts literally disappeared.
-
2 months ago | 
jdsupra.com | Michele Borens |Jeffrey Friedman |Timothy A. Gustafson
The California Franchise Tax Board (FTB) has proposed amendments to its regulations that govern how sales of services and intangibles are sourced for income tax purposes. The changes to this income tax apportionment regulation will apply to nearly every corporation that pays California tax. Comments regarding these proposed changes are due no later than February 5, 2025.
-
2 months ago | 
belfercenter.org | Eric Rosenbach |Ethan Lee |Bethany Russell |Jeffrey Friedman
Speaker: Mary Bridges, Ernest May Fellow in History & Policy, International Security ProgramInfrastructure projects have long been central to the exercise of U.S. power, both domestically and abroad. This talk introduces the concept of “infrastructure statecraft”—the interplay of engineering expertise, finance, and state authority in shaping durable networks of power.
-
Dec 17, 2024 | 
taxexecutive.org | Jeffrey Friedman |Sebastian G. Iagrossi
Every state that imposes a corporate income tax requires multistate businesses to apportion business income. The states’ methods of apportioning income, however, vary considerably and can produce inconsistent results. The United States Supreme Court sanctioned these differences in Moorman Mfg. Co. v.
-
Nov 21, 2024 | 
foreignaffairs.com | Jeffrey Friedman
During the 2024 presidential campaign, the U.S. foreign policy establishment was virtually united in declaring Donald Trump unfit to serve as commander in chief. More than 100 Republican national security leaders joined with Democrats to endorse Kamala Harris, condemning Trump as an aspiring autocrat who would upend the U.S.-built global order.
-
Oct 23, 2024 | 
mondaq.com | Jeffrey Friedman
In the ever-evolving landscape of commercial real estate,
neighborhood retail leasing stands out as a stalwart performer. Despite challenges faced by other asset classes, neighborhood
retail continues to exhibit strength and stability. Let us delve
into the key factors driving its success.
In the first half of 2024, the national retail vacancy rate
remained at an impressive 4.1%. This resilience is attributed to
increased demand and fewer tenant bankruptcies.
-
Oct 8, 2024 | 
foreignaffairs.com | Jeffrey Friedman
In the run-up to the 1992 U.S. presidential election between Bill Clinton and George H. W. Bush, Clinton campaign strategist James Carville famously coined the phrase, “It’s the economy, stupid.” The quip has been an article of faith for political commentators ever since. Presidential elections, according to this logic, are decided by bread-and-butter issues: domestic politics, not foreign policy, is what matters.
-
Sep 19, 2024 | 
pnas.org | Jeffrey Friedman |Peter Grünwald |Wanqian Li |Siyuan He
When the long-awaited results of a clinical trial of the wildly popular weight loss drug semaglutide were published in late 2023, the moment marked a milestone in cardiovascular medicine. A once-weekly injection of semaglutide slashed the incidence of death from cardiovascular causes and nonfatal heart attacks or strokes in nondiabetic patients with a history of heart disease as well as obesity or overweight (1).
